INC Research, InVentiv Health To Merge - Quick Facts

(RTTNews) - INC Research Holdings, Inc. (INCR), a Phase I-IV Contract Research Organization or CRO, Wednesday announced that it has agreed to merge with inVentiv Health, Inc., a privately held, global CRO and Contract Commercial Organization or CCO.

The Boards of Directors of both companies have unanimously approved a definitive merger agreement pursuant to which their businesses would combine in an all-stock transaction, creating a biopharmaceutical solutions organization.

The transaction values inVentiv at an enterprise value of approximately $4.6 billion, based upon the closing price of INC Research common stock on Tuesday. The combined company would be at an enterprise value of approximately $7.4 billion.

Upon closing of the transaction, INC Research shareholders are expected to own approximately 53 percent and inVentiv shareholders are expected to own approximately 47 percent of the combined company on a fully diluted basis.

Advent International and Thomas H. Lee Partners, two preeminent private equity firms, are currently equal equity owners of inVentiv and will remain investors in the combined company upon closing of the merger.